DexCom Expects Organic Revenue Growth of Above 10% Per Year Through 2030

MT Newswires Live05-15 22:12

DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030.

Among the targets, initially disclosed at the company's investor day event on Thursday, are a 2030 non-GAAP gross profit margin of 67% to 69%, as well as a 2030 non-GAAP operating profit margin of 29% to 30%, DexCom said.

The company expects adjusted earnings before interest, taxes, depreciation, and amortization, or EBITDA, margin of 36% to 37% in 2030.

DexCom also said its board has approved a share buyback program of up to $1 billion, with a repurchase period ending no later than June 30, 2027.

The board terminated an existing share buyback plan, of which $250 million were available, the company said.

Price: 61.50, Change: +3.68, Percent Change: +6.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment